Evidence map›Paper›PMID 38193534›Full record

ArticleJCI insight2024

Unique macrophage phenotypes activated by BMP signaling in breast cancer bone metastases.

Claire L Ihle, Desiree M Straign, Johana A Canari, Kathleen C Torkko, Kathryn L Zolman, Elizabeth E Smith, Philip Owens

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Hierarchical Targeting of TREM2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Macrophage heterogeneity in bone metastasis.Journal of bone oncology · 2024
    Article
  9. New Strategies for Macrophage Re-Education in Cancer: An Update.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Claire L IhleDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Desiree M StraignDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Johana A CanariCase Western Reserve University, Cleveland, Ohio, USA.
Kathleen C TorkkoDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Kathryn L ZolmanDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Elizabeth E SmithDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Philip OwensDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
University of Colorado Anschutz Medical Campus · USCase Western Reserve University · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NRSA Training CoreTL1TR002533 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CICUTTO, LISA · 2018 to 2022
$3.0M
Targeting the BMP pathway in metastatic cancerIK2BX002929 · VA · VETERANS HEALTH ADMINISTRATION · PI OWENS, PHILIP · 2016 to 2021
–
ShEEP Request for Nanostring nCounter Spring ProfilerIS1BX003572 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI KEITH, ROBERT · 2016 to 2016
–
BLRD VA IK2 BX002929BLRD VA IS1 BX003572NCATS NIH HHS TL1 TR002533NCI NIH HHS P30 CA046934
6 · The paper itself

Abstract

Metastatic breast cancer (mBC) tissue in bone was systematically profiled to define the composition of the tumor microenvironment. Gene expression identified a high myeloid signature of patients with improved survival outcomes. Bone metastases were profiled by spatial proteomics to examine myeloid populations within the stroma that correlated with macrophage functions. Single-cell spatial analysis uncovered macrophage activation in the stroma of mBC bone lesions. Matched BC patient samples of primary breast tumor and bone metastasis tissues were compared for gene expression in the bone, where bone morphogenetic protein 2 (BMP2) was most significantly upregulated. Immune cell changes from breast to bone demonstrated a loss of lymphoid cells but a consistent population of macrophages. BMP-activated macrophages were increased uniquely in bone. Bone marrow-derived macrophage activation coupled with BMP inhibition increased inflammatory responses. Using experimental mouse models of mBC bone metastasis and trained immunity, we found that BMP inhibition restricts progression of metastases early in the macrophage activation state but not after tumors were established in the bone. This study revealed unique myeloid BMP activation states that are distinctly integrated with bone metastases.

Indexed as

Bone Morphogenetic ProteinsBone NeoplasmsBreast NeoplasmsMacrophagesAnimalsBone and BonesFemaleHumansMicePhenotypeTumor MicroenvironmentBone Morphogenetic ProteinsBreast cancerImmunologyInnate immunityOncology

Identifiers

PMID38193534
PMCPMC10906463
OpenAlexW4390659739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.